The reagents, kits, and consumables accounted for the largest market share in the infectious disease diagnostics market, by product & service, during the forecast period
The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services.
The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021.
Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages.
This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.
Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases.
In 2021, the mosquito-borne diseases segment accounted for the highest CAGR.
Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021.
This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence